CVS Will Retain $300M In Drug Rebates In 2018, PBM Says
CEO Merlo downplays importance of rebates to the firm’s financials as he rebuts accusations that PBMs cause high list prices for drugs.
You may also be interested in...
Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.
Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.